| Product Unit Size | Cost | Quantity | Stock |
|---|
AMG-337 is a highly selective inhibitor of c-Met. In MET-amplified and MET-high-expressing preclinical models of hepatocellular carcinoma, AMG-337 significantly inhibited tumor growth. It has also shown promise in other studies of patients with Met-amplified advanced solid tumors.
| Cas No. | 1173699-31-4 |
|---|---|
| Purity | ≥99% |
| Formula | C23H22FN7O3 |
| Formula Wt. | 463.47 |
| IUPAC Name | 6-{(1R)-1-[8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one |
| Synonym | AMG 337, AMG337 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Du Z., Caenepeel S., et al. Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma. Mol Cancer Ther. 15(6):1227-37 (2016). PMID: 27196749.
Hong D., LoRusso P., et al. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 25(8):2403-13 (2019). PMID: 30425090.